EC Pulmonology and Respiratory Medicine

Sarcoidosis is a multisystem inflammatory disease of unknown cause, characterized by the formation of non-caseating granulomas in various organs, particularly the lungs and the lymphatic system. Although pulmonary involvement is the most common, sarcoidosis can also affect the central and peripheral nervous systems, leading to a wide range of manifestations. Among these manifestations, bilateral hypoacusis, that is, a decrease in hearing on both sides, can occur due to the involvement of cranial nerves, particularly the vestibulocochlear nerve (cranial nerve VIII). Although rare this impairment can be a revealing feature of the disease, although it is rare. Patients may experience progressive or sudden hearing loss, sometimes accompanied by vertigo or tinnitus. The diagnosis is based on a combination of clinical, radiological, and histopathological criteria, including the biopsy of suspected lesions to confirmation the characteristic granulomas.The treatment of sarcoidosis with neurological involvement generally includes corticosteroids to reduce granulomatous inflammation. In some cases, immunosuppressants may be used in combination with or as an alternative to corticosteroids, depending on the therapeutic response and side effects. Multidisciplinary management is essential to optimize the treatment and follow-up of patients with multisystem sarcoidosis with neurological manifestations. We report the case of a patient presenting with bilateral hearing loss revealed multisystemic sarcoidosis.

 Keywords: Multi-System Sarcoidosis; Hearing Loss; Vestibulocochlear Nerve; Diffuse Interstitial Lung Disease

1. Stern BJ., et al. “Definition and consensus diagnostic criteria for neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group”. JAMA Neurology12 (2018): 1546-1553.
2. Fritz D., et al. “Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis”. BMC Neurology1 (2016): 220.
3. Tana C., et al. “Challenges in the diagnosis and treatment of neurosarcoidosis”. Annals of Medicine 7 (2015): 576-591.
4. Gerke AK. “Treatment of sarcoidosis: a multidisciplinary approach”. Frontiers in Immunology 11 (2020): 545413.
5. Vorselaars ADM., et al. “Methotrexate vs azathioprine in second-line therapy of sarcoidosis”. Chest3 (2013): 805-812.
6. Baughman RP., et al. “Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement”. American Journal of Respiratory and Critical Care Medicine 7 (2006): 795-802.
7. Gerke AK., et al. “Disease burden and variability in sarcoidosis”. Annals of the American Thoracic Society 6 (2017): S421-S428.
8. Antoniu SA. “Infliximab for the therapy of chronic sarcoidosis, Baughman RP, Drent M, Kavuru M et al.: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. (2006) 174(7):795-802”. Expert Opinion on Investigational Drugs 5 (2007): 753-756.
9. Crawford F., et al. “Neurosarcoidosis presenting as isolated bilateral cerebellopontine angle tumors: case report and review of the literature”. Ear, Nose and Throat Journal8 (2019): NP120-NP124.
10. Judson MA. “An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment”. Chest 4 (1999): 1158-1165.